Affiliations: [a] Department of Pathology, Benefis Hospital, Great Falls, MT, USA
| [b] Department of Medicine, Valley Hospital Medical Center, Las Vegas, NV, USA
| [c] Jefferson College of Pharmacy, Philadelphia, PA, USA
| [d] Jacqmar, Inc., Minneapolis, MN, USA
Correspondence:
[*]
Corresponding author: Gregory D. Sloop, M.D., Department of Pathology, Benefis Hospitals, 1101 26th St. S., Great Falls, MT 59405, USA. Tel.: +406 455 4446; E-mails: [email protected]; [email protected].
Abstract: Uric acid may be a risk factor for atherosclerotic cardiovascular disease, although the data conflict and the mechanism by which it may cause cardiovascular disease is uncertain. This study was performed to test the hypothesis that uric acid, an anion at physiologic pH, can cause erythrocyte aggregation, which itself is associated with cardiovascular disease. Normal erythrocytes and erythrocytes with a positive direct antiglobulin test for surface IgG were incubated for 15 minutes in 14.8 mg/dL uric acid. Erythrocytes without added uric acid were used as controls. Erythrocytes were then examined microscopically for aggregation. Aggregates of up to 30 erythrocytes were noted when normal erythrocytes were incubated in uric acid. Larger aggregates were noted when erythrocytes with surface IgG were incubated in uric acid. Aggregation was negligible in controls. These data show that uric acid causes erythrocyte aggregation. The most likely mechanism is decreased erythrocyte zeta potential. Erythrocyte aggregates will increase blood viscosity at low shear rates and increase the risk of atherothrombosis. In this manner, hyperuricemia and decreased zeta potential may be risk factors for atherosclerotic cardiovascular disease.
